Alnylam Pharmaceuticals Inc (NAS:ALNY)
$ 165.72 8.3 (5.27%) Market Cap: 20.96 Bil Enterprise Value: 19.89 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 67/100

Alnylam Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 06:30PM GMT
Release Date Price: $114.65 (-3.86%)
Anupam Rama
JP Morgan Chase & Co, Research Division - VP and Analyst

Okay. We'll go ahead and get started. This -- thanks, everyone, for attending here, the 2020 JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Tessa Romero and Matt Bannon from the team. Our next presenting company is Alnylam, and presenting on behalf of the company is CEO, John Maraganore. John?

John M. Maraganore
Alnylam Pharmaceuticals, Inc. - CEO & Executive Director

Great. Well, thanks, Anupam. Joining me on the stage this morning are Pushkal Garg, our CMO; Barry Greene, our President; Yvonne Greenstreet, our COO; Jeff Poulton, our CFO; and Akshay Vaishnaw, our President of R&D.

Now 10 years ago on this stage, we suggested that the 2010s might be the RNA decade. Well, if you look at what happened to Alnylam over the last 10 years, we actually might have been right. We started the decade in 2010 as a company that was -- I think most people thought we weren't going to necessarily make it,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot